Symptoms and General Pathology

All Conditions

Neoplasms

Rare Diseases

Recurrence

Glioma

Glioblastoma

Astrocytoma

Neoplasms, Neuroepithelial

Neuroectodermal Tumors

Neuroectodermal Tumors, Primitive

Neoplasms, Germ Cell and Embryonal

Neoplasms by Histologic Type

Neoplasms, Glandular and Epithelial

Neoplasms, Nerve Tissue

Neuroepithelioma

Antineoplastic Agents

All Drugs and Chemicals

Bevacizumab

Antineoplastic Agents, Immunological

Angiogenesis Inhibitors

Growth Inhibitors

Standard treatment associated with circulating leucocytes (blood samplings)

Bevacizumab standard of care

Veronique QUILLIEN, MD

Bevacizumab, a monoclonal antibody against vascular endothelial growth factor (VEGF), is an antiangiogenic treatment currently proposed to recurrent high grade glioma patients. Unfortunately some patients fail to respond to this treatment and finding biological factors allowing the discrimination between potential responders and non responders would be very helpful. As the immune system plays a key role in angiogenesis induction and maintenance in cancer, it could serve as a surrogate marker of angiogenesis in cancer patients.

The purpose of this study is to determine the influence of bevacizumab treatment on circulating immune cells in high grade glioma patients and to search for a link between the variation of these cells and the response to treatment.

The following leucocyte subsets will be analyzed in whole blood before treatment and before cycles 3, 5 and 7:

* Classical, intermediate, nonclassical and Tie2 expressing monocytes.
* Regulatory T cells (Treg).
* Myeloid Derived Suppressor cells (MDSCs) The variation of the absolute numbers (or relative percentages) of the cells in the blood of patients will be correlated to the response to treatment assessed according to the RANO criteria.

Search for a Link Between Response to Treatment and Circulating Leucocytes in High Grade Glioma Patients

Analysis of Different Circulating Immune Cells in Patients With Recurrent Glioblastoma or Mixed Anaplasic Glioma Treated With Bevacizumab and Search for a Link With Response to Treatment

Analysis of blood cells populations variation during treatment with bevacizumab. Last sampling planned before the 7th cycle of bevacizumab.

Relationship between variation of blood cells and RMI response after 6 weeks of treatment

Link between variation of analyzed cellular population and survival.

Center Eugene Marquis

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Search for a Link Between Response to Treatment and Circulating Leucocytes in High Grade Glioma Patients	NCT01836536	Glioblastoma Glioma	Bevacizumab sta...	18 Years -	Center Eugene Marquis
Search for a Link Between Response to Treatment and Circulating Leucocytes in High Grade Glioma Patients	NCT01836536	Glioblastoma Glioma	Bevacizumab sta...	18 Years -	Center Eugene Marquis

Spots Global Cancer Trial Database for bevacizumab standard of care